Introduction To study the long-term evolution of patient-reported outcome measures (PROMs) in the most common spinocerebellar ataxias (SCAs), we analyzed 8 years follow-up data of the EUROSCA Natural History Study, a cohort study of 526 patients with SCA1, SCA2, SCA3 and SCA6. Methods To assess the functional capacity in daily living, we used the functional assessment (part IV) of the Unified Huntington's Disease Rating Scale (UHDRS-IV), for health-related quality of life the visual analogue scale of the EuroQol Five Dimensions Questionnaire (EQ-5D VAS), and for depressive symptoms the Patient Health Questionnaire (PHQ-9). Severity of ataxia was assessed using the Scale for the Assessment and Rating of Ataxia (SARA) and neurological symptoms other than ataxia with the Inventory of Non-Ataxia Signs (INAS). 
Introduction
The spinocerebellar ataxias (SCAs) are autosomal dominantly inherited neurodegenerative diseases with prominent ataxia that lead to progressive disability during the disease course. The SCAs are clinically and genetically heterogeneous and more than 40 genetically different types have been defined. The most common SCAs that together account for more than half of all affected families are SCA1, SCA2, SCA3 and SCA6. These subtypes are caused by translated CAG repeat expansions that encode elongated polyglutamine tracts within the proteins associated with each type. Patients with SCA1, SCA2 and SCA3 frequently present with additional neurological signs. Conversely, SCA6 is considered an almost purely cerebellar disorder [1] .
Recently, considerable progress has been made in characterizing progression of ataxia and additional neurological symptoms, but less is known about the progression of patient-reported outcome measures (PROMs). PROMs are increasingly recognized as valuable and essential for evaluating clinical care and treatment. Recently, the US-FDA developed a patient-reported outcome guidance related to the use of PROMs used to support drug approvals [2] . PROMs are collected through short, self-completed questionnaires and measure patient`s subjective perception of health status. PROMs therefore provide important information beyond neurological scales [3, 4] .
Previous cross-sectional studies reported that subjective health perception of SCA patients was impaired specifically due to functional impairment, pain and depressive symptoms [5] . As in other neurodegenerative diseases, the prevalence of depressive symptoms in SCA was higher than estimates from populations surveys [6] [7] [8] .
To study the evolution of PROMs including functional capacity in daily living, health-related quality of life and depressive symptoms as well as to identify factors that influence this evolution, we analysed long-term data of the EUROSCA Natural History Study, a multicentric longitudinal cohort study of 525 patients with either SCA1, SCA2, SCA3 or SCA6 [9] [10] [11] .
Methods

Study design
In an 8-year longitudinal cohort study, 525 patients with genetically confirmed SCA1, SCA2, SCA3 and SCA6 were recruited at 17 European ataxia referral centers which together form the EUROSCA Clinical Group. Assessments were done annually within 3 months around the specified time point for the first 3 years. Thereafter, participants entered an extension phase in which study visits were scheduled in connection with routine visits resulting in irregular intervals.
Assessments were done according to a written study protocol. The study was approved by the ethics committees of the participating centres and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all study participants.
This study is registered with ClinicalTrials.gov, number NCT02440763.
Procedures
Functional capacity in daily living was assessed using the functional assessment (part IV) of the Unified Huntington's Disease Rating Scale (UHDRS) [12] , a checklist of 25 common daily tasks yielding a sum score ranging from 0 to 25 by giving a score of 1 to each task the patient can perform.
To assess health-related quality of life we used the visual analogue scale (VAS) of the EuroQol Five Dimensions Questionnaire (EQ-5D) [<link rid="bib13">13</link>] For calculation, the patient is asked to mark the present day's health status on a scale with end points of 0 and 100, indicating the "the worst" (0) and "the best health you can imagine" (100). To add qualitative information on healthrelated quality of life, we additionally used the descriptive system of EQ-5D comprising five dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state in each of the five dimensions, resulting in a 1-digit number that expresses the level selected for that dimension.
To assess the severity of depressive symptoms, the depression scale of the Patient Health Questionnaire (PHQ-9) was used [14] . The PHQ-9 is a nine-item self-rating questionnaire that simply scores each of the nine DSM-IV criteria for depressive disorders. The severity of depression is calculated by assigning scores of 0, 1, 2, and 3, to the response categories "not at all", "several days", "more than half the days" and "nearly every day" respectively. The sum score ranges from 0 (absence of depression) to 27 (severe depression).
Severity of ataxia was assessed using the Scale for the Assessment and Rating of Ataxia (SARA) yielding a sum score that ranges from 0 to 40, with 0 indicating the absence and 40 the most severe degree of ataxia [15] . Neurological symptoms other than ataxia were assessed using the Inventory of Non-Ataxia Signs (INAS), yielding a sum score from 0 to 16 by counting the number of clinical signs (INAS count) [16] .
Statistical analysis
To investigate whether baseline characteristics of patients who had been followed only for the initial 3 years (± 3 months) differed from those of patients who had been followed longer, we used t tests for quantitative and Chi square tests for categorical variables.
For analysis of disease progression, a linear mixed model was applied with random effects on intercept and slope. The 1 3 time variable was the year since inclusion. Because of the presence of a floor effect for a non-negligible part of the sample for the analysis of the PHQ-9, we used a curvilinear mixed model [17] . Curvilinear modelling takes into account that differences between two successive levels of the scale do not have a constant meaning and that the distribution of the scale greatly deviates from the normal distribution that is assumed in the linear mixed model. We used a spline link function for all SCAs. Linearity of the progression rate was tested via nested models (likelihood ratio test). Specifically, we tested for a linear and quadratic effect of time and chose the model that best fitted the data. To verify that dropouts did not affect the results, we used a pattern-mixture model to obtain an unbiased estimation of progression if the effect of disease duration was significant [18] . For comparison of the progression rates between the genotypes, the pattern-mixture model was adjusted to the genotype.
To identify factors that influenced progression of PROMs, the tested factor was added in interaction with the linear mixed model used for analysis, taking into account the missing data model of progression. The tested factors were the SARA, INAS, PHQ-9 and the presence of double vision, dysphagia, urinary dysfunction and cognitive impairment at baseline, sex, age at onset, disease duration and repeat length of the expanded and normal allele. Influence of these variables on the progression rates was tested via interactions between the given factor and the time variable. Independent factors that were significant in the univariate analysis were included in a multivariate model, including the interactions with backward selection. Estimates derived from the model are given as mean (SE).
To determine the sensitivity for change of the PROMs in comparison to the neurological scales, we calculated the standardized response mean (SRM), defined as mean score change per year divided by the standard deviation (SD) of the variation as effect size index. Values of 0.20, 0.50 and 0.80 were considered to represent small, moderate and large changes, respectively [19] .
Statistical analyses were performed with SAS 9.3 software (SAS Institute, Cary, NC). All tests were two-sided. Test results were considered significant at the 0.05 level. Bonferroni correction was used for comparison of disease progression between genotypes.
Results
The study population consisted of 525 patients with SCA1, SCA2, SCA3 or SCA6. Analyses were performed in a subgroup of 462 patients who had at least one follow-up visit. 415 patients were seen for a follow-up visit after 1 year, 416 after 2 years, and 336 after 3 years. All following visits were done at irregular intervals. Flowcharts detailing the number of patients seen each year, reasons for dropout and demographic data are given in the Supplementary appendix [11] . While disease duration and SARA scores at baseline were similar in all genotypes, SCA6 patients had an older age at inclusion, older age of onset and lower number of non-ataxia signs. UHDRS-IV (p = 0.8924), EQ-5D-VAS (p = 0.2412) and PHQ-9 (p = 0.1394) did not differ between the genotypes at baseline. There was no difference in the frequencies of the use of anti-depressants between the genotypes (p = 0.8600).
We first compared patients who had been followed only for the initial 3 years period with those who had been followed longer. No group differences were observed in sex, age at inclusion, age at onset and repeat length of both, expanded and normal allele. However, in patients with a shorter follow-up, disease duration was longer (SCA1, SCA2) and SARA (SCA1, SCA2, SCA3) and INAS scores (SCA1, SCA3) were higher [11] . The decline of UHDRS-IV scores best fitted with a linear model in all genotypes. As UHDRS-IV decline was faster in SCA2-patients with a maximum follow-up of 3 years, we applied a pattern-mixture model that allowed calculating an average annual decline of − 1.35 (0.12) in SCA1, − 1.15 (0.11) in SCA2, − 1.16 (0.11) in SCA3, and − 0.99 (0.12) in SCA6 (Fig. 1) . The decline did not differ between the genotypes (p = 0.3042). To identify factors that were independently associated with faster decline, we applied multivariate modelling. In SCA1, higher SARA scores were associated with lower UHDRS-IV scores at baseline [ (Table 1) .
EQ-5D VAS decline best fitted with a linear model in all genotypes. The average decline was − 2.88 (0.72) per year in SCA1, − 1.97 (0.49) in SCA2, − 2.06 (0.55) in SCA3, and − 1.03 (0.57) in SCA6 (Fig. 2) . The decline did not differ between the genotypes (p = 0.2993). In SCA1, we found that higher SARA scores [− 0.7374 (0.18), p < 0.001] and the presence of dysphagia [− 8.6842 (3.37), p = 0.0113] at baseline were associated with lower EQ-5D-VAS scores. Furthermore, the presence of dysphagia at baseline attenuated the decline to 2.46 (0.99) (p = 0.0157), whereas longer repeat expansions [− 0.2264 (0.09), p = 0.0176] were associated with faster decline. We failed to identify factors associated with EQ-5D-VAS decline in SCA2, SCA3 and SCA6 (Table 1) .
With regard to the five dimensions of subjective health perception, impairment of self-care increased in all genotypes with an average of 0. The evolution of PHQ-9 sum score was described with a curvilinear mixed model in all genotypes. The progression was similar between patients who have been followed only for the initial 3 year period and those who have been fol- To identify factors that were independently associated with faster PHQ-9 progression, we applied multivariate modeling (Table 1) . In SCA1 patients, progression was faster for patients with cognitive impairment [0.14 (0. 
Discussion
Our study provides a comprehensive account of the longterm evolution of PROMs including functional capacity in daily living, health-related quality of life and depressive symptoms in the most common SCA disorders that steadily change over the entire observational period. As there was no validated measure of functional capacity specific for ataxic patients available at the start of our study, we decided to use UHDRS-IV. This scale was developed for assessment of patients with Huntington´s disease [12] . However, the use seemed appropriate as patients with ataxia and Huntington`s disease face qualitatively similar functional limitations in daily life. In addition, in the SARA validation trials, UHDRS-IV was strongly correlated with SARA [15] . For assessment of subjective health perception we applied EQ-5. As other visual analogue scales, EQ-5D VAS has the inherent problem of the end-of-scale bias, i.e. the extreme ends of the scale are less likely to be used. On the other hand, EQ-5D is easy to use, available in validated translations in different languages and provides quantitative and qualitative information about patient's perception of health state. Depression is known to have a major impact on subjective health perception in various neurodegenerative diseases [5, 20] . In this study, we used PHQ-9 to assess the severity of depression. A previous study in SCA patients proved that PHQ-9 is a valid instrument to detect clinical relevant Fig. 2 Progression rates of EQ-5D VAS for each SCA-subtype depression [5] . PHQ-9 is a brief self-rating questionnaire that is known for its excellent feasibility, reliability, validity and sensitivity, but lower specificity and positive predictive value [21] [22] [23] . Overall, it has been shown to be a valid measure of depression in different cultures and translations [24] . The use of PHQ-9 in ataxia patients is complicated by the fact that one of the nine items is related to slowness of movements and speech which may be due to ataxia rather than reflecting depressive mood (Fig. 3) . The strengths of our study include the large number of patients and the long observational period of up to 8 years. However, there was a considerable dropout rate. In our previous analysis of the evolution of ataxia and neurological symptoms in this cohort, we found that the dropout rate was particularly high in those who had a longer disease duration (SCA1,SCA2) and greater disease severity at baseline (SCA1,SCA2,SCA3). Correspondingly, in SCA1, SCA2 and SCA3, baseline UHDRS-IV scores, and, in SCA1 and SCA6, EQ-5D-VAS scores were lower in patients that were followed only for the initial 3 years. To account for the dropout and estimate PROM evolution in an unbiased way, we applied a pattern-mixture model approach. Pattern-mixture models consider missing data as a random process which means that the probability of having missing data depends on the other observed information. The average evolution is thus estimated as the weighted mean of the evolution in the group with a follow-up of maximally 3 years and the evolution in the group with extended follow-up.
In the last years, PROMs are increasingly considered as relevant outcome measures as they directly assess patient`s perception of health status and may better reflect the impact of the disease on everyday life than clinical scales. The most important finding of our analysis is that all three measures, functional capacity, health-related quality of life and mood, deteriorated over the entire observation period in all genotypes. The 2-year longitudinal CRC-SCA study did not find an increase of PHQ-9 in SCA1, SCA2, SCA3 and SCA6 [7] . This is in line with previous studies in Huntington`s disease that did not find an increase of depression at any stage of disease [25, 26] . The reason for the discrepancy to our findings may be the shorter observation time of the other studies. Although we observed steady changes of all PROMs, the effect sizes, which could be determined for methodological reasons only for UHDRS-IV and EQ-5D, were considerably smaller than that of SARA. The use of UHDRS-IV or EQ-5D as a primary outcome measure in a clinical trial would thus be associated with much larger patient numbers. Our previous analysis of the evolution of ataxia severity in this cohort revealed that progression was fastest in SCA1, intermediate in SCA2 and SCA3, and slowest in SCA6 [11] . In contrast, the present analysis did not show significant differences of the change rate of the PROMs between the genotypes. This may be simply due to the larger variability of the PROMs resulting in a lack of power, but may also be due to the fact that PROMs reflect different aspects of the disease than clinical scales, such as SARA.
In SCA1, SARA was a determinant of the UHDRS-IV and EQ-5D VAS baseline and the UHDRS-IV rate of decline. Furthermore, the length of the expanded allele, which is a major determinant of SARA progression in SCA1, was associated with faster decline of UHDRS-IV and EQ-5D VAS in SCA1. On the other hand, we did not find a major influence of SARA on any PROM in SCA2, SCA3 and SCA6. This is in line with studies in other neurodegenerative disorders that have shown that patient´s subjective health perception is only partly related to clinical assessment of disease-related impairment, but may be also influenced by other factors such as emotional well-being and other comorbidities [27] . INAS, which is a measure of extracerebellar involvement, affected both baseline UHDRS-IV and UHDRS-IV decline in SCA3. These observations underline the view that, although severity of neurological involvement, as measured by SARA and INAS, has an impact on functional capacity and subjective health perception, it only explains a part of the variablity of these PROMs. In SCA1, functional capacity appears to be strongly related to ataxia, whereas in SCA3 which is the prototype of a SCA with a highly pleomorphic phenotype neurological symptoms other than ataxia influence functional capacity [28] . Depressive symptoms were mainly influenced by nonmotor features, such as cognitive impairment (SCA1), as well as urinary dysfunction and male sex (SCA2). Similarly, the authors of the CRC-SCA study concluded that depressive symptoms are not simply the consequence of motor disability [7] . In our study, cognitive impairment was solely assessed according to the clinical impression of the examiner. This impression may be confounded for example by the occurrence of depressive pseudo-dementia; however, prevalence of relevant depressive syndrome was not high in this study. However, the influence of cognitive impairment on the evolution of UHDRS-IV and PHQ-9 in SCA1 has to be interpreted with caution.
Our study gives useful information on the long-term evolution of PROMs in the common SCAs. The decline of functional capacity and quality of life along with the increase of depressive symptoms was partly related to deterioration of motor abilities, but was not fully explained by them. In the common SCAs, PROMs thus give complementary 
